A lot smaller upfront payment than first thought·
Initial consideration value of US$10 million, which includes non-dilutive equity in the SPV;
Ajan Reginald, Roquefort Therapeutics CEO commented:"We are pleased to announce this therapeutic licencing deal with an initial payment which is likely to include $1.25-2.5M upfront and a 24% share of what is substantial potential upside.
Ann: Pause in Trading, page-8
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AN1 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $3.229M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 197835 | 0.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.8¢ | 7500 | 1 |
View Market Depth
| Last trade - 16.12pm 02/08/2024 (20 minute delay) ? |
| AN1 (ASX) Chart |
Day chart unavailable